Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

New Name And Focus For Lexicon Genetics

February 5, 2007 | A version of this story appeared in Volume 85, Issue 6

Lexicon Genetics is changing its name to Lexicon Pharmaceuticals to reflect a shift of focus to drug discovery and development. Lexicon has declared its intention to advance 10 drug candidates, identified through its gene knockout technology, into human clinical trials by 2010. Currently, Lexicon has two compounds in clinical trials-one to treat cognitive disorders including Alzheimer's and one to treat irritable bowel syndrome-and expects to file Investigational New Drug Applications for two additional ones this year. The firm says it will reallocate financial and human resources from genetics research to drug development programs without a change in operating expenses.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.